Health & Biotech
End in sight as Opthea looks to be key player in US$10 billion wet AMD market
Health & Biotech
Weed Week: Cannabis can ‘kill melanoma’; and Germany legalises weed possession
Health & Biotech
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
Health & Biotech
AdAlta’s Ad-214 extension study reaches milestone for Phase II clinical studies and partnering
Health & Biotech
ASX Health Stocks: Atomo pops 90pc after purchase order; AdAlta up 20pc on Phase 1 results
Health & Biotech
Nova Eye Medical hits new US sales record following improved uptake of iTrack Advance products
Health & Biotech
ASX Health Stocks: Healius rips higher as new CEO takes over; Nova Eye bags record US sales
Health & Biotech
ASX Health Stocks: Polynovo to get first orders in India; Clinuvel reports good results from Phase 2
Health & Biotech
ScoPo’s Powerplays: Health stocks fall as tight hospital budgets hurt Nanosonics
Health & Biotech
ASX Health Stocks: EMV gets strategic US$15m investment from NYSE-listed giant
Health & Biotech
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Health & Biotech
PharmAust’s MPL could offer MND/ALS patients up to 56.5 months additional life expectancy
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.